Abstract: The disclosure provides methods the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and for treatment of psychiatric symptoms of viral, bacterial, and autoimmune encephalitis, and for protecting or reinforcing the blood-brain barrier, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A.

Abstract: The dynamic package sortation device includes a track for handling a plurality of packages is provided. At least one conveyor extends away from the track towards at least two shipping containers. The at least one conveyor is extendable and retractable for dispensing the packages into a first shipping container of the at least two shipping containers and a second condition for dispensing the packages into a second shipping container of the at least two shipping containers. A controller is provided for providing an instruction to move the at least one conveyor between the first condition and the second condition based on a trigger.

Abstract: A wheel fastener alarm assembly is provided having a fastener body with a first portion defining a wrenching surface and a cavity, and a second portion with a threaded portion to attach and detach from a wheel of a vehicle. A sensor array is disposed in the cavity of fastener body to detect an attribute of the fastener body and generate an output signal based on the attribute of the fastener body. An antenna connected to the sensor array to transmit the signal to a remote location. A cap is secured to the first portion of the fastener body and covers the wrenching surface and the cavity opening to define a capped fastener body.

Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.

Abstract: The invention relates to pharmaceutical compositions comprising the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.

Abstract: The invention relates to particular substituted (3?,5?-3-hydroxy-pregnan-20-ones, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as sedatives, hypnotics, anxiolytics, and/or anesthetics, and methods for treatment of depression, anxiety, insomnia, epilepsy, and other central nervous system disorders, as well as to combinations with other agents.

Abstract: The disclosure provides methods the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and for treatment of psychiatric symptoms of viral, bacterial, and autoimmune encephalitis, and for protecting or reinforcing the blood-brain barrier, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A.

Abstract: The invention relates to a particular substituted heterocycle fused gamma carboline, the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.

Abstract: An interchangeable module configured to be used in an integrated perforating gun and setting tool system, the interchangeable module having a body having a chamber, a first electrical connection located at a first end of the chamber, and a second electrical connection located at a second end of the chamber. The first end is opposite to the second end. An addressable switch located inside the chamber, the addressable switch has a digital address. A connection unit located inside the chamber and configured to electrically connect the addressable switch to an initiating device. The interchangeable module is configured to be used (1) between a first gun cluster and a second gun cluster and (2) between a distal gun cluster and a setting tool, and the first and second electrical connections are electrically connected to the addressable switch.

Abstract: An interchangeable module configured to be used in an integrated perforating gun and setting tool system, the interchangeable module having a body having a chamber, a first electrical connection located at a first end of the chamber, and a second electrical connection located at a second end of the chamber. The first end is opposite to the second end. An addressable switch located inside the chamber, the addressable switch has a digital address. A connection unit located inside the chamber and configured to electrically connect the addressable switch to an initiating device. The interchangeable module is configured to be used (1) between a first gun cluster and a second gun cluster and (2) between a distal gun cluster and a setting tool, and the first and second electrical connections are electrically connected to the addressable switch.

Abstract: The invention relates to a particular substituted heterocycle fused gamma-carboline, the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.

Abstract: The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and/or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A/D2 receptor ligand, for example a substituted heterocycle fused gamma-carboline as described herein, in free, pharmaceutically acceptable salt or prodrug form, and (ii) a nitric oxide donor, separately (sequentially or simultaneously), or in combination (e.g., in a fixed dose combination).

Abstract: The disclosure relates to methods of administering comprising administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and/or prophylaxis of renal disorders, such as chronic kidney disease. Related compounds and methods of making are further defined.

Abstract: Behavioral pharmacological data with the compound of formula (1), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that SHT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.

Abstract: The disclosure provides methods, treatments and materials for treating diseases or disorders associated with the dopamine D1 receptor intracellular pathway. In particular, the present disclosure provides for methods of treating such diseases and disorders in combination with a dopamine replacement therapy.

Abstract: The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, including methods of treatment and pharmaceutical compositions for use therein.

Abstract: An interchangeable module configured to be used in an integrated perforating gun and setting tool system, the interchangeable module having a body having a chamber, a first electrical connection located at a first end of the chamber, and a second electrical connection located at a second end of the chamber. The first end is opposite to the second end. An addressable switch located inside the chamber, the addressable switch has a digital address. A connection unit located inside the chamber and configured to electrically connect the addressable switch to an initiating device. The interchangeable module is configured to be used (1) between a first gun cluster and a second gun cluster and (2) between a distal gun cluster and a setting tool, and the first and second electrical connections are electrically connected to the addressable switch.

Abstract: An interchangeable module is configured to be used in an integrated perforating gun and setting tool system. The interchangeable module includes a body having first external threads; an addressable switch located inside the body; and a connection unit located inside the body and configured to electrically connect to an initiating device. The interchangeable module is configured to be used (1) between a first gun cluster and a second gun cluster and (2) between a distal gun cluster and a setting tool.

Abstract: The present disclosure relates to the treatment of schizophrenia in adults, comprising the administration of pharmaceutical capsules comprising 42 mg of lumateperone (60 mg of lumateperone tosylate).

Abstract: A downhole system includes a switch sub holding a gun switch and an adapter attached to the switch sub and holding an igniter switch. The gun switch is configured to detonate a detonator, and the igniter switch is configured to ignite an igniter system.